The FDA approved Roivant’s brepocitinib, branded as Lisraya, for dermatomyositis—an oral therapy Roivant’s unit Priovant licensed from Pfizer. The approval provides a new steroid-sparing option for a rare autoimmune disease marked by muscle weakness and a painful skin rash. Roivant said the treatment is dosed once daily and targets the underlying immune biology driving dermatomyositis. For decades, high-dose steroids and other immune-suppressing agents have been the standard of care, leaving many patients with incomplete control and adverse effects. The approval comes with commercial expectations for a “hub-and-spoke” strategy built around rare disease franchises, while also testing payer and guideline adoption for an oral non-biologic option. The FDA nod positions Lisraya as a meaningful addition to the competitive landscape of immune-mediated rare diseases, where treatment choice increasingly depends on tolerability and durability as much as efficacy.